The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants
Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
The transaction improves patient experience, patient outcomes and aims to reduce health care costs
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
OptumRx to make Pear’s three commercial Prescription Digital Therapeutics accessible to patients with Optum formulary access.
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
Company working on COVID vaccine INO 4800
Subscribe To Our Newsletter & Stay Updated
